{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:27:23Z","timestamp":1793330843954,"version":"4.5.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.leukres.2024.107479","type":"journal-article","created":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T16:20:24Z","timestamp":1710174024000},"page":"107479","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123"],"prefix":"10.1016","volume":"139","author":[{"given":"Xiaoyi","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asiri","family":"Ediriwickrema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atif","family":"Saleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Pemmaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel N.","family":"Mannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2024.107479_bib1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.leukres.2018.08.014","article-title":"Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm","volume":"73","author":"Guru Murthy","year":"2018","journal-title":"Leuk. Res."},{"issue":"17","key":"10.1016\/j.leukres.2024.107479_bib2","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","article-title":"Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm","volume":"380","author":"Pemmaraju","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.leukres.2024.107479_bib3","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s11899-019-00556-2","article-title":"Updates in novel therapies for blastic plasmacytoid dendritic cell neoplasm (BPDCN)","volume":"14","author":"Economides","year":"2019","journal-title":"Curr. Hematol. Malig. Rep."},{"issue":"26","key":"10.1016\/j.leukres.2024.107479_bib4","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1200\/JCO.22.00034","article-title":"Long-Term benefits of tagraxofusp for patients with blastic plasmacytoid dendritic cell neoplasm","volume":"40","author":"Pemmaraju","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.leukres.2024.107479_bib5","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1177\/1078155220951850","article-title":"Tagraxofusp followed by combined azacitidine and venetoclax in blastic plasmacytoid dendritic cell neoplasm: a case report and literature review","volume":"27","author":"Samhouri","year":"2021","journal-title":"J. Oncol. Pharm. Pr."},{"issue":"10","key":"10.1016\/j.leukres.2024.107479_bib6","doi-asserted-by":"crossref","first-page":"e354","DOI":"10.1111\/1346-8138.15456","article-title":"Apparent partial loss of CD123 expression in blastic plasmacytoid dendritic cell neoplasm after treatment with CD123-targeted therapy: a novel finding and possible diagnostic pitfall","volume":"47","author":"Aung","year":"2020","journal-title":"J. Dermatol."},{"issue":"5","key":"10.1016\/j.leukres.2024.107479_bib7","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/j.1365-2141.2009.07679.x","article-title":"Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia","volume":"145","author":"Garnache-Ottou","year":"2009","journal-title":"Br. J. Haematol."},{"issue":"11","key":"10.1016\/j.leukres.2024.107479_bib8","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1172\/JCI128571","article-title":"DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance","volume":"129","author":"Togami","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"11","key":"10.1016\/j.leukres.2024.107479_bib9","doi-asserted-by":"crossref","first-page":"4590","DOI":"10.1172\/JCI132443","article-title":"Hitting the bullseye with a nonlethal payload: resistance in CD123-positive malignancies","volume":"129","author":"Gondek","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"12","key":"10.1016\/j.leukres.2024.107479_bib10","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1007\/s00277-020-04276-z","article-title":"Venetoclax monotherapy for cutaneous blastic plasmacytoid dendritic cell neoplasm","volume":"99","author":"Schwede","year":"2020","journal-title":"Ann. Hematol."},{"issue":"2","key":"10.1016\/j.leukres.2024.107479_bib11","doi-asserted-by":"crossref","first-page":"E62","DOI":"10.1002\/ajh.26417","article-title":"Venetoclax and hypomethylating agents in older\/unfit patients with blastic plasmacytoid dendritic cell neoplasm","volume":"97","author":"Gangat","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"9","key":"10.1016\/j.leukres.2024.107479_bib12","doi-asserted-by":"crossref","first-page":"e432","DOI":"10.3324\/haematol.2018.214635","article-title":"Daratumumab for treatment of blastic plasmacytoid dendritic cell neoplasm. A single-case report","volume":"104","author":"Iversen","year":"2019","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.leukres.2024.107479_bib13","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1158\/2159-8290.CD-16-0999","article-title":"Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to venetoclax","volume":"7","author":"Montero","year":"2017","journal-title":"Cancer Discov."},{"issue":"7","key":"10.1016\/j.leukres.2024.107479_bib14","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1056\/NEJMc1814963","article-title":"More on blastic plasmacytoid dendritic-cell neoplasms","volume":"380","author":"Pemmaraju","year":"2019","journal-title":"N. Engl. J. Med"},{"issue":"12","key":"10.1016\/j.leukres.2024.107479_bib15","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1080\/10428194.2021.1941938","article-title":"Daratumumab-based therapy after prior Azacytidine-Venetoclax in an octagenerian female with BPDCN (blastic plasmacytoid dendritic cell neoplasm) - a new perspective","volume":"62","author":"Mirgh","year":"2021","journal-title":"Leuk. Lymphoma"},{"issue":"3","key":"10.1016\/j.leukres.2024.107479_bib16","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ajh.25000","article-title":"Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies","volume":"93","author":"DiNardo","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"4","key":"10.1016\/j.leukres.2024.107479_bib17","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.3324\/haematol.2020.247569","article-title":"Immunophenotypic characterization of reactive and neoplastic plasmacytoid dendritic cells permits establishment of a 10-color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasm","volume":"106","author":"Wang","year":"2021","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.leukres.2024.107479_bib18","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/asheducation-2016.1.16","article-title":"Treatment of blastic plasmacytoid dendritic cell neoplasm","volume":"2016","author":"Sullivan","year":"2016","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"issue":"1","key":"10.1016\/j.leukres.2024.107479_bib19","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1186\/s13256-021-02939-7","article-title":"Venetoclax in relapsed\/refractory blastic plasmacytoid dendritic cell neoplasm with central nervous system involvement: a case report and review of the literature","volume":"15","author":"Albiol","year":"2021","journal-title":"J. Med. Case Rep."},{"issue":"15","key":"10.1016\/j.leukres.2024.107479_bib20","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1182\/blood.2021011817","article-title":"Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm","volume":"138","author":"Pemmaraju","year":"2021","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212624000456?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212624000456?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T23:06:24Z","timestamp":1720134384000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212624000456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":20,"alternative-id":["S0145212624000456"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107479","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107479","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107479"}}